When stratified by gender, we saw a trend towards increased prevalence of ALK+ IHC in HR+ NSCLC versus HR- NSCLC in females (9/97, 9.28% vs. 14/405, 3.46%, p = 0.0259, q=0.0518) but not in males (1/66, 1.52% vs. 7/484, 1.45%, p>0.9999, q >0.9999) (Table 5, Figure 2C). The gene discussed is ALK; the disease is non-small cell lung carcinoma.